Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other solid neoplasm 1Genitourinary 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Sarcoma 6Rhabdomyosarcoma 5Sarcoma, Synovial 3Osteosarcoma 3Sarcoma, Ewing 2Neuroectodermal Tumors, Primitive, Peripheral 2Liposarcoma 2Leiomyosarcoma 2Hemangiosarcoma 2Fibrosarcoma 2Wilms Tumor 1Retinoblastoma 1Neurofibrosarcoma 1Neuroectodermal Tumors, Primitive 1Neuroectodermal Tumors 1Neuroblastoma 1Malignant mesenchymal tumor 1Histiocytoma, Malignant Fibrous 1Hepatoblastoma 1Hemangiopericytoma, Malignant 1Desmoplastic Small Round Cell Tumor 1Dermatofibrosarcoma 1Chondrosarcoma, Extraskeletal Myxoid 1Adrenocortical Carcinoma 1

Interventions

Oncolytic Virotherapy 2repotrectinib 1pembrolizumab 1pamiparib 1interferon gamma-1b 1cixutumumab 1Vincristine 1Thiotepa 1Temozolomide 1Radiation 1Peripheral Blood Stem Cell Transplantation 1ONC206 1Melphalan 1Interferon-gamma 1Immunotherapy 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Erlotinib Hydrochloride 1Doxorubicin 1Cyclophosphamide 1Busulfan 1Bone Marrow Transplantation 1Antibodies, Monoclonal 1Amifostine 1Afatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroectodermal Tumors × cixutumumab × Sarcoma × Clear all
NCT00831844 2015-03-30

Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 2 Completed
116 enrolled 8 charts
CNSEndocrineGastrointestinalGenitourinaryOther solid neoplasmSarcoma

Wilms Tumor, Neuroblastoma, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Neuroectodermal Tumors, Hepatoblastoma, Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡